Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Stock Information for GeoVax Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About GeoVax Labs Inc.

GeoVax to Participate in Upcoming Investor Conferences in September
GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market
Registration is Now Open for Tribe Public's Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab's CEO
GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
GeoVax to Present at the Emerging Growth Conference on August 21, 2024
GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board
GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.